Abstract:Drug interactions in patients receiving multiple drug regimens are a constant concern for the clinician. With the increased availability of new drugs and their concomitant use with other drugs, there has been a rise in the potential for adverse drug interactions as demonstrated by the recent withdrawals of newly marketed drugs because of unacceptable interaction profiles. Therefore, the interaction potential of a new compound has to be assessed in detail, starting with preclinical in vitro and in vivo studies at candidate selection and continuously followed up through preclinical and clinical development. Since formal in vivo studies of all possible drug interactions are neither practicable nor suggestive, a careful selection of a limited number of drug combinations to be investigated in vivo during the development phase is indicated. Based on knowledge of pharmacokinetic and biopharmaceutical properties, a well balanced link between in vitro investigations and carefully selected in vivo interaction studies allows full assessment of the potential of a new drug to cause clinically relevant pharmacokinetic drug-drug interactions, prediction of a lack of interactions and derivation of the proper dose recommendations.Clinical pharmacology plays a number of key roles within the process of collecting information on drug interactions during preclinical and clinical development: addressing issues and/or favourable properties to be expected, thus contributing to the scientific assessment of development potential; setting up a rational in vivo drug-drug interaction programme; performing early mechanistic studies to link in vitro with in vivo information (employing ‘cocktail’ approaches if possible); reviewing co-medication sections for clinical trials; and conducting labelling-oriented interaction studies after proof of concept.The fact that interactions can occur between various active substances should by itself be a conclusive argument against unnecessary polypharmacy. Prescribing fewer drugs on a rational basis can reduce the risk of adverse effects secondary to drug interactions and may help to improve the quality of drug treatment and to save costs.

In Vitro/In Vivo Correlation for Drug-Drug Interactions

Prediction of Metabolic Drug Interaction in vivo by Using in vitro Drug Metabolism Data

Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development

In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions

Prediction of metabolizing enzyme-mediated clinical drug interactions using in vitro information

Screening of drug candidates for their drug–drug interaction potential

In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery

Usage of In Vitro Metabolism Data for Drug‐Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration

Development of novel tools for the in vitro investigation of drug-induced liver injury

Advances in Predicting of Drug-Drug Interaction in Vivo by Using Cytochrome P450 Mechanism-Based Inhibition Data in Vitro

Predicting Inhibitory Drug—Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants

Drug interactions evaluation: An integrated part of risk assessment of therapeutics

Evaluation of models for predicting drug-drug interactions due to induction

In Silico Methods for Predicting Drug–drug Interactions with Cytochrome P-450s, Transporters and Beyond

Computational Methods for Inference and Prediction of Novel Drug-Drug Interactions

Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment

General Framework to Quantitatively Predict Pharmacokinetic Induction Drug-Drug Interactions Using In Vitro Data

Application of Mechanism-Based CYP Inhibition for Predicting Drug–drug Interactions

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

Drug—drug interaction through molecular structure similarity analysis